Raxatrigine (INN, USAN) (formerly CNV1014802, GSK-1014802) is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. In June 2014, Convergence presented positive results for a phase II clinical study of raxatrigine in the treatment of TGN, including findings that the drug had an excellent efficacy and safety profile and was well-tolerated.[non-primary source needed]

CAS：934240-30-9
中文别名：
英文别名：
分子式：C18H19FN2O2
分子量：314.354
精确质量：314.143
Psa：65.34
Logp：4.1616

MDL号：MFCD28900694

储存条件：2-8°C，避光，保存于惰性气体中